KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--CSL Biotherapies, a subsidiary of one of the world’s leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has approved Afluria® (influenza virus vaccine) for active immunization of persons age 18 years and older against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. Today’s approval marks the company’s first entry into the U.S. vaccine market.
